SAN DIEGO, Oct. 23, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today that John Turanin, vice president and general manager, Zogenix technologies, is scheduled to make a presentation that highlights successful repositioning of injectable sumatriptan for migraine with a novel needle-free delivery technology at the 2 nd Annual Drug Repositioning & Indications Discovery Conference, which is being held on October 23-24, 2012 in San Francisco, Calif. The case study demonstrates increased physician and patient adoption of a standard therapy when enhanced with the DosePro ® Needle-free Delivery System.
Zogenix To Present New Case Study Highlighting Successful Repositioning Of Injectable Sumatriptan For Migraine With A Novel Needle-Free Delivery Technology
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.